Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Receivables (2020 - 2025)

Neuroone Medical Technologies' Change in Receivables history spans 6 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 36.27% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $292954.0, down 83.95%, while the annual FY2025 figure was $1.1 million, 516.05% up from the prior year.
  • Change in Receivables reached $1.4 million in Q4 2025 per NMTC's latest filing, up from $1.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.2 million in Q4 2024 to a low of -$2.1 million in Q1 2025.
  • Average Change in Receivables over 5 years is $154221.8, with a median of $11956.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: skyrocketed 892.25% in 2023, then tumbled 16849.45% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$23708.0 in 2021, then soared by 361.86% to $62082.0 in 2022, then skyrocketed by 775.29% to $543399.0 in 2023, then soared by 303.44% to $2.2 million in 2024, then tumbled by 36.27% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Change in Receivables are $1.4 million (Q4 2025), $1.3 million (Q3 2025), and -$318780.0 (Q2 2025).